VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis

EMBO Journal

Volumn 24, Issue 13, 2005, Pages 2342-2353

  Matsumoto, Taro ^a,b   Bohman, Svante ^a   Dixelius, Johan ^a   Berge, Tone ^c   Dimberg, Anna ^a   Magnusson, Peetra ^a   Wang, Ling ^d   Wikner, Charlotte ^a   Qi, Jian Hua ^e   Wernstedt, Christer ^f   Wu, Jiong ^g   Bruheim, Skjalg ^h   Mugishima, Hideo ^b   Mukhopadhyay, Debrabata ^d   Spurkland, Anne ^c   Claesson Welsh, Lena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF OSLO   (Norway)

^d MAYO CLINIC   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UPPSALA UNIVERSITY   (Sweden)

^g CELL SIGNALING TECHNOLOGY   (United States)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Actin cytoskeleton; TSAd; Tumor angiogenesis; Tyrosine phosphorylation site; VEGFR 2

Indexed keywords

ACTIN; ADAPTOR PROTEIN; BROXURIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TSAD; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CYCLE S PHASE; CELL MIGRATION; CONTROLLED STUDY; CYTOSKELETON; ENDOTHELIUM CELL; GENE MUTATION; IMMUNOPRECIPITATION; MITOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TUMOR VASCULARIZATION;

ACTINS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CELL LINE, TUMOR; CELLS, CULTURED; ENDOTHELIAL CELLS; FIBROSARCOMA; HUMANS; KIDNEY NEOPLASMS; MICE; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STEM CELLS; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 22744447871     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.emboj.7600709     Document Type: Article

References (27)

1. Boyer SJ (2002) Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. Curr Top Med Chem 2: 973-1000
2. Brockington A, Lewis C, Wharton S, Shaw PJ (2004) Vascular endothelial growth factor and the nervous system. Neuropathol Appl Neurobiol 30: 427-446
3. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583
4. Choi YB, Kim CK, Yun Y (1999) Lad, an adapter protein interacting with the SH2 domain of p56lck, is required for T cell activation. J Immunol 163: 5242-5249
5. Dixelius J, Makinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, Alitalo K, Claesson-Welsh L (2003) Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Biol Chem 278: 40973-40979
6. Dougher M, Terman BI (1999) Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 18: 1619-1627
7. Dougher-Vermazen M, Hulmes JD, Bohlen P, Terman BI (1994) Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. Biochem Biophys Res Commun 205: 728-738
8. Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29: 10-14
9. Frame MC (2004) Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 117: 989-998
10. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364
11. Holmqvist K, Cross MJ, Rolny C, Hagerkvist R, Rahimi N, Matsumoto T, Claesson-Welsh L, Welsh M (2004) The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem 279: 22267-22275
12. Ito N, Wernstedt C, Engstrom U, Claesson-Welsh L (1998) Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules. J Biol Chem 273: 23410-23418
13. Kabrun N, Buhring HJ, Choi K, Ullrich A, Risau W, Keller G (1997) Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development 124: 2039-2048
14. Kendall RL, Rutledge RZ, Mao X, Tebben AJ, Hungate RW, Thomas KA (1999) Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues. J Biol Chem 274: 6453-6460
15. Lamalice L, Houle F, Jourdan G, Huot J (2004) Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 23: 434-445
16. Magnusson P, Rolny C, Jakobsson L, Wikner C, Wu Y, Hicklin DJ, Claesson-Welsh L (2004) Deregulation of Flk-1/vascular endothelial growth factor receptor-2 in fibroblast growth factor receptor-1-deficient vascular stem cell development. J Cell Sci 117: 1513-1523
17. Matsumoto T, Claesson-Welsh L (2001) VEGF receptor signal transduction. Sci STKE 2001: RE21
18. Qi JH, Claesson-Welsh L (2001) VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp Cell Res 263: 173-182
19. Rajagopal K, Sommers CL, Decker DC, Mitchell EO, Korthauer U, Sperling AI, Kozak CA, Love PE, Bluestone JA (1999) RIBP, a novel Rlk/Txk- and itk-binding adaptor protein that regulates T cell activation. J Exp Med 190: 1657-1668
20. Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M (2005) Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci USA 102: 1076-1081
21. Spurkland A, Brinchmann JE, Markussen G, Pedeutour F, Munthe E, Lea T, Vartdal F, Aasheim HC (1998) Molecular cloning of a T cell-specific adapter protein (TSAd) containing an Src homology (SH) 2 domain and putative SH3 and phosphotyrosine binding sites. J Biol Chem. 273: 4539-4546
22. Sundvold V, Torgersen KM, Post NH, Marti F, King PD, Rottingen JA, Spurkland A, Lea T (2000) T cell-specific adapter protein inhibits T cell activation by modulating Lck activity. J Immunol 165: 2927-2931
23. Takahashi T, Yamaguchi S, Chida K, Shibuya M (2001) A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 20: 2768-2778
24. Wu LW, Mayo LD, Dunbar JD, Kessler KM, Ozes ON, Warren RS, Donner DB (2000) VRAP is an adaptor protein that binds KDR, a receptor for vascular endothelial cell growth factor. J Biol Chem 275: 6059-6062
25. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434
26. Zeng H, Sanyal S, Mukhopadhyay D (2001) Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 276: 32714-32719
27. Zeng H, Zhao D, Mukhopadhyay D (2002) KDR stimulates endothelial cell migration through heterotrimeric G protein Gq/11-mediated activation of a small GTPase RhoA. J Biol Chem 277: 46791-46798